No Data
No Data
Revance Therapeutics Cut to Equal-Weight From Overweight by Barclays
Revance Therapeutics Analyst Ratings
Barclays Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $7
Revance has been acquired for 0.924 billion U.S. dollars! Fosun Pharma (600196.SH) holds exclusive commercialization rights for its star botulinum toxin product in China.
Revance is acquired for $0.924 billion.
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Has Obtained a Fair Price for Its Public Shareholders
H.C. Wainwright Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.6
No Data
No Data